AR030273A1 - Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina - Google Patents
Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquinaInfo
- Publication number
- AR030273A1 AR030273A1 ARP010101098A ARP010101098A AR030273A1 AR 030273 A1 AR030273 A1 AR 030273A1 AR P010101098 A ARP010101098 A AR P010101098A AR P010101098 A ARP010101098 A AR P010101098A AR 030273 A1 AR030273 A1 AR 030273A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- heteroaryl
- heterocyclyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
Abstract
Compuestos de hidroxifenil urea sustituidos con sulfonamidas, de formula (1) o sal farmacéuticamente aceptables de los mismos, en donde Rb se selecciona independientemente del grupo que consta de hidrogeno, NR6R7, OH, Ora, alquilo C1-5 arilo, aril-alquilo C1-4 aril-alquenilo C2-4, cicloalquilo, cicloalquilo-alquilo C1-5, heteroarilo, heteroaril-alquilo C1-4, heteroaril-alquenilo C2-4, heterociclilo, heterociclil-alquilo C1-4 y un resto heterociclil-alquenilo C2-4, restos que pueden estar opcionalmente sustituidos de una a tres veces independientemente con un sustituyente seleccionado del grupo que consta de halogeno, nitro, alquilo C1-4 sustituido con halo, alquilo C1-4 amino, amina mono û o dialquilo C1-4sustituida, ORa, C(O)Ra, NRaC(O)ORa, OC(O)NR6R7, hidroxi, NR9C(O)Ra, S(O)m'Ra, C(O)NR6R7 C(O)OH, C(O)Ora, S(O)2NR6R7 y NHS(O)2Ra o los sustituyentes Rb se unen para formar un anillo de 3-10 miembros, opcionalmente sustituido y que contiene, además de carbono, independientemente, de 1 a 3 restos opcionalmente sustituidos seleccionados del grupo que consta de NRa, O, S, SO y SO2; Ra se selecciona del grupo que consta de alquilo, arilo, arilalquilo C1-4, heteroarilo, heteroaril-alquilo C1-4, heterociclilo, COORa, y un resto heterociclil-alquilo C2-4, restos todos que pueden estar opcionalmente sustituidos; m es un numero entero que tiene un valor de 1 a 3; m' es 0 o un numero entero que tiene un valor de 1 o 2; n es un numero entero que tiene un valor de 1 a 3; q es 0 o un numero entero que tiene un valor de 1 a 10; t es 0, o un numero entero que tiene un valor de 1 o 2; s es un numero entero que tiene un valor de 1 a 3; R1 se selecciona independientemente del grupo que consta de hidrogeno, halogeno, nitro, ciano, alquilo C1-10, alquilo C1-10 sustituido con halo, alquenilo C2-10, alcoxi C1-10, alcoxi C1-10 sustituido con halo, azida, S(O)tR4, (CR8R8)qS(O)tR4, hidroxi, alquilo C1-4 hidroxi sustituido, arilo, aril-alquilo C1-4 aril alquenilo C2-10 ariloxi, aril-alcoxi C1-4, heteroarilo, hetroarilalquilo, heteroaril-alquenilo C2-10, heteroaril-alquiloxi C1-4, heterociclilo, heterociclilalquilo C1-4, heterociclil-alquiloxi C1-4, heterociclil-alquenilo C2-10, (CR8R8)qNR4R5, (CR8R8)qC(O)-NR4R5, alquenilo C2-10C(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alquenilo C2-10C(O)R11, alquenilo C2-10C(O)-OR11, (CR8R8)qC(O)R11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qC(NR4)NR4R5, (CR8R8)qNR4C(NR5)R11, (CR8R8)qNHS(O)2R13, y (VR8R8)qS(O)2NR4R5, o dos restos R1, conjuntamente pueden formar O-(CH2)sO o un anillo saturado o insaturado de 5 a 6 miembros, tal que los restos de alquilo, arilo, arilalquilo o heterociclilo pueden estar opcionalmente sustituidos; R4 y R5 se seleccionan independientemente del grupo que consta de hidrogeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, aril-alquilo C1-4 opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaril-alquilo C1-4 opcionalmente sustituido, heterociclilo, y heterociclil-alquilo C1-4 o R4 y R5 junto con el nitrogeno al que están unidos forman un anillo de 5 a 7 miembros que opcionalmente puede comprender un heteroátomo adicional seleccionado de O, N y S; R6 y R7 se seleccionan independientemente del grupo que consta de hidrogeno, alquilo C1-4, heteroarilo, arilo, alquilarilo y alquil C1-4-heteroalquilo; o R6 y R7 junto con el nitrogeno al que están unidos forman un anillo de 5 a 7 miembros, anillo que opcionalmente puede contener un heteroátomo adicional que se selecciona del grupo que consta de oxígeno, nitrogeno o azufre y anillo que puede estar opcionalmente sustituido; Y se selecciona del grupo que consta de furano, tiofeno, pirrol, oxazol, imidazol, tiazol, tieno (2-3-b) piridina, pirazol, isooxazol, isotiazol, 1,2,3- o 1,2,4-oxadiazol, 1,2,3û o 1,2,4-triazol, 1,2,3- o 1,2,4-tiadiazol, piridina, piridina-N-oxido, pirimidina, piridazina, pirazina 1,3,5- o 1,2,3- o 1,2,4-triazina, 1,2,4,5-tetrazina, indol, benzofurano, indazol, bencimidazol, benzotiazol, quinolina, isoquinolina, cinolina, ftalazina, quinazolina y quinoxalina, restos todos que pueden estar 1-3 veces sustituidos con R1; R8 es hidrogeno o alquilo C1-4; R9 es hidrogeno o alquilo C1-4, R10 es alquilo C1-10-C(O)2R8; R11 se selecciona del grupo que consta de hidrogeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, aril-alquilo C1-4 opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaril-alquilo C1-4 opcionalmente sustituido, heterociclilo opcionalmente sustituido; y heterociclil-alquilo C1-4 opcionalmente sustituido; y R13 se selecciona del grupo que consta de alquilo C1-4, arilo, aril-alquilo C1-4, heteroarilo, heteroaril-alquilo C1-4, heterociclilo y heterociclil-alquilo C1-4. También se dan a conocer composiciones farmacéuticas que los comprenden y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18841000P | 2000-03-10 | 2000-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030273A1 true AR030273A1 (es) | 2003-08-20 |
Family
ID=22693024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101098A AR030273A1 (es) | 2000-03-10 | 2001-03-08 | Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina |
Country Status (26)
Country | Link |
---|---|
US (1) | US6608077B2 (es) |
EP (1) | EP1261336B1 (es) |
JP (1) | JP2003535820A (es) |
KR (1) | KR20020083174A (es) |
CN (1) | CN1635979A (es) |
AR (1) | AR030273A1 (es) |
AT (1) | ATE353215T1 (es) |
AU (2) | AU2001245606B2 (es) |
BR (1) | BR0109002A (es) |
CA (1) | CA2402891A1 (es) |
CO (1) | CO5271660A1 (es) |
CY (1) | CY1106514T1 (es) |
CZ (1) | CZ20023007A3 (es) |
DE (1) | DE60126480T2 (es) |
DK (1) | DK1261336T3 (es) |
ES (1) | ES2280350T3 (es) |
HU (1) | HUP0302003A3 (es) |
IL (1) | IL151431A0 (es) |
MX (1) | MXPA02008818A (es) |
MY (1) | MY133845A (es) |
NO (1) | NO20024193L (es) |
NZ (1) | NZ520912A (es) |
PL (1) | PL363118A1 (es) |
PT (1) | PT1261336E (es) |
WO (1) | WO2001068568A2 (es) |
ZA (1) | ZA200207216B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR030689A1 (es) * | 2000-03-14 | 2003-09-03 | Smithkline Beecham Corp | Compuestos de 3-aminosulfonil-2-hidroxifenil urea, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades mediadas por quimioquinas |
CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
AR030753A1 (es) * | 2000-09-25 | 2003-09-03 | Smithkline Beecham Corp | Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas |
GB0124848D0 (en) * | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
US7056925B2 (en) | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
AR041834A1 (es) * | 2002-10-29 | 2005-06-01 | Smithkline Beecham Corp | Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
CA2547410C (en) | 2003-12-03 | 2013-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,2,3-triazole amide derivatives as inhibitors of cytokie production |
EP1812008A4 (en) * | 2004-10-20 | 2008-10-29 | Smithkline Beecham Corp | ANTAGONISTS OF THE IL-8 RECEPTOR |
AU2007240364A1 (en) * | 2006-04-21 | 2007-11-01 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
PL2009992T3 (pl) * | 2006-04-21 | 2012-11-30 | Glaxosmithkline Llc | Antagoniści receptora IL-8 |
PE20080943A1 (es) * | 2006-06-23 | 2008-09-27 | Smithkline Beecham Corp | Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8 |
US10647665B2 (en) | 2016-06-22 | 2020-05-12 | Fudan University | Biaryl urea derivative or salt thereof and preparation process and use for the same |
CN107522641B (zh) * | 2016-06-22 | 2020-05-05 | 复旦大学 | 联芳基脲类衍生物或其盐及其制备方法和用途 |
CN111727184B (zh) * | 2018-01-11 | 2022-06-28 | 深圳嘉科生物科技有限公司 | Cxcr2拮抗剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11503110A (ja) | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体拮抗剤 |
IL127666A0 (en) * | 1996-06-27 | 1999-10-28 | Smithkline Beecham Corp | IL-8 receptor antagonists |
UY25842A1 (es) * | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
-
2001
- 2001-03-08 AR ARP010101098A patent/AR030273A1/es not_active Application Discontinuation
- 2001-03-08 MY MYPI20011072A patent/MY133845A/en unknown
- 2001-03-09 NZ NZ520912A patent/NZ520912A/en unknown
- 2001-03-09 HU HU0302003A patent/HUP0302003A3/hu unknown
- 2001-03-09 KR KR1020027011807A patent/KR20020083174A/ko not_active Application Discontinuation
- 2001-03-09 AT AT01918542T patent/ATE353215T1/de not_active IP Right Cessation
- 2001-03-09 DK DK01918542T patent/DK1261336T3/da active
- 2001-03-09 CZ CZ20023007A patent/CZ20023007A3/cs unknown
- 2001-03-09 EP EP01918542A patent/EP1261336B1/en not_active Expired - Lifetime
- 2001-03-09 PL PL01363118A patent/PL363118A1/xx not_active Application Discontinuation
- 2001-03-09 AU AU2001245606A patent/AU2001245606B2/en not_active Ceased
- 2001-03-09 ES ES01918542T patent/ES2280350T3/es not_active Expired - Lifetime
- 2001-03-09 CA CA002402891A patent/CA2402891A1/en not_active Abandoned
- 2001-03-09 AU AU4560601A patent/AU4560601A/xx active Pending
- 2001-03-09 US US10/220,772 patent/US6608077B2/en not_active Expired - Fee Related
- 2001-03-09 IL IL15143101A patent/IL151431A0/xx unknown
- 2001-03-09 CN CNA018062563A patent/CN1635979A/zh active Pending
- 2001-03-09 PT PT01918542T patent/PT1261336E/pt unknown
- 2001-03-09 WO PCT/US2001/007746 patent/WO2001068568A2/en active IP Right Grant
- 2001-03-09 DE DE60126480T patent/DE60126480T2/de not_active Expired - Fee Related
- 2001-03-09 BR BR0109002-0A patent/BR0109002A/pt not_active IP Right Cessation
- 2001-03-09 MX MXPA02008818A patent/MXPA02008818A/es not_active Application Discontinuation
- 2001-03-09 JP JP2001567669A patent/JP2003535820A/ja active Pending
- 2001-03-12 CO CO01019686A patent/CO5271660A1/es not_active Application Discontinuation
-
2002
- 2002-09-03 NO NO20024193A patent/NO20024193L/no unknown
- 2002-09-09 ZA ZA200207216A patent/ZA200207216B/en unknown
-
2007
- 2007-04-16 CY CY20071100520T patent/CY1106514T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60126480D1 (de) | 2007-03-22 |
EP1261336A4 (en) | 2004-12-15 |
CZ20023007A3 (cs) | 2003-04-16 |
ZA200207216B (en) | 2004-07-21 |
EP1261336B1 (en) | 2007-02-07 |
EP1261336A2 (en) | 2002-12-04 |
DE60126480T2 (de) | 2007-06-14 |
PT1261336E (pt) | 2007-03-30 |
NO20024193D0 (no) | 2002-09-03 |
ES2280350T3 (es) | 2007-09-16 |
JP2003535820A (ja) | 2003-12-02 |
BR0109002A (pt) | 2004-08-17 |
AU4560601A (en) | 2001-09-24 |
PL363118A1 (en) | 2004-11-15 |
WO2001068568A2 (en) | 2001-09-20 |
CA2402891A1 (en) | 2001-09-20 |
CO5271660A1 (es) | 2003-04-30 |
MY133845A (en) | 2007-11-30 |
DK1261336T3 (da) | 2007-06-04 |
IL151431A0 (en) | 2003-04-10 |
WO2001068568A3 (en) | 2002-03-21 |
NO20024193L (no) | 2002-09-03 |
KR20020083174A (ko) | 2002-11-01 |
AU2001245606B2 (en) | 2006-03-09 |
NZ520912A (en) | 2005-02-25 |
HUP0302003A3 (en) | 2005-06-28 |
ATE353215T1 (de) | 2007-02-15 |
US6608077B2 (en) | 2003-08-19 |
CY1106514T1 (el) | 2012-01-25 |
CN1635979A (zh) | 2005-07-06 |
US20030055286A1 (en) | 2003-03-20 |
HUP0302003A2 (hu) | 2003-11-28 |
MXPA02008818A (es) | 2006-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030273A1 (es) | Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina | |
GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
CO5261605A1 (es) | Compustos farmaceuticos | |
AR039189A1 (es) | Compuesto de pirrolopiridazina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
AR039127A1 (es) | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento | |
ES2162656T3 (es) | Derivados de quinazolina. | |
AR039917A1 (es) | Compuesto de pirrol, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
DK0880508T3 (da) | Quinazolinderivater som VEGF-inhibitorer | |
AR030053A1 (es) | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
MY144042A (en) | Quinazoline compounds | |
KR950704304A (ko) | 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives) | |
NO20085077L (no) | Nye forbindelser | |
AR041672A1 (es) | Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo | |
RU2006113880A (ru) | Макроциклические ингибиторы сериновой протеиназы ns3 вируса гепатита с | |
DE60142469D1 (de) | Imidinderivate als antineoplastika | |
AR060287A1 (es) | Compuesto de 5,6 dihidro-3h-pirrolo[1,2,3-de]quinoxalini-3-ona, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuesto intermediario util para su preparacion | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
AR039419A1 (es) | Compuesto de benzopiran-4-ona, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
MX2009007954A (es) | Derivado de heterocicliden-n-(aril) acetamida. | |
AR040644A1 (es) | Un moduladores del receptor de progesterona benzoxazina-2-tiona, una composicion farmaceutica, uso del compuesto para preparar un dedicamento para tratar una enfermedad neoplasica-hormona-dependiente y el uso de un compuesto benzoxazina-2-tiona, benzoxazina-2-ilideno cianamida o benzoxazina-2-iliden | |
AR030391A1 (es) | Composicion para tratar un estado de enfermedad mediado por quimioquinas y el uso de la misma para la manufactura de un medicamento. | |
AR033803A1 (es) | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |